Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 17/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29446947 | 0.89 | F10 (0.66) | F10CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL15065018 | 0.89 | F10 (0.66) | F10CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL30146333 | 0.89 | F10 (0.66) | F10CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL78772 | 0.89 | F10 (0.66) | F10CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL460444 | 0.89 | F10 (0.66) | F10CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL29651806 | 0.89 | F10 (0.66) | F10CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL2994083 | 0.85 | F10 (0.53) | F10 | |
| SCHEMBL15319214 | 0.83 | F10 (0.75) | F10CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL15857655 | 0.83 | F10 (0.56) | F10CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL19338281 | 0.83 | F10 (0.51) | F10CYP1A2CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013098833-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | CADILA HEALTHCARE LIMITED (IN) | 2013-07-04 | — | — | WO | claimed |
| EP-2459555-B1 | PROCESSES FOR CRYSTALLIZATION OF RIVAROXABAN | KRKA D D NOVO MESTO (SI) | 2021-11-03 | — | — | EP | disclosed |
| US-20140378682-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | CADILA HEALTHCARE LIMITED (IN) | 2014-12-25 | — | — | US | disclosed |
| WO-2013098833-A2 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | CADILA HEALTHCARE LIMITED (IN) | 2013-07-04 | — | — | WO | disclosed |
| EP-2459555-A1 | PROCESSES FOR CRYSTALLIZATION OF RIVAROXABAN | KRKA, D.D., Novo Mesto (SI) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011012321-A1 | PROCESSES FOR CRYSTALLIZATION OF RIVAROXABAN | KRKA, D.D., NOVO MESTO (SI) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378682-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING RIVAROXABAN | VKORC1, VKORC1L1, F2 | F10 11/4885CYP1A2 16/4885CYP2C9 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.